AU2004269361B2 - Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells - Google Patents

Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells Download PDF

Info

Publication number: AU2004269361B2
Authority: AU; Australia
Prior art keywords: cells; neurons; population; neural; cell
Prior art date: 2003-08-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

AU2004269361A

Other languages

English (en)

Other versions

AU2004269361A1 (en

Inventor

Xue-Jun Li

Su-Chun Zhang

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Wisconsin Alumni Research Foundation

Original Assignee

Wisconsin Alumni Research Foundation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-29

Filing date

2004-08-27

Publication date

2010-05-20

2004-08-27 Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation

2005-03-10 Publication of AU2004269361A1 publication Critical patent/AU2004269361A1/en

2010-05-20 Application granted granted Critical

2010-05-20 Publication of AU2004269361B2 publication Critical patent/AU2004269361B2/en

2024-08-27 Anticipated expiration legal-status Critical

Status Expired legal-status Critical Current

Links

210000002569 neuron Anatomy 0.000 title claims description 171
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title claims description 132
238000000034 method Methods 0.000 title claims description 76
229960003638 dopamine Drugs 0.000 title claims description 66
210000002161 motor neuron Anatomy 0.000 title claims description 65
210000001671 embryonic stem cell Anatomy 0.000 title claims description 14
210000001178 neural stem cell Anatomy 0.000 title claims description 10
230000004069 differentiation Effects 0.000 title description 74
238000000338 in vitro Methods 0.000 title description 20
241000288906 Primates Species 0.000 title description 5
210000004027 cell Anatomy 0.000 claims description 529
230000001537 neural effect Effects 0.000 claims description 120
210000001259 mesencephalon Anatomy 0.000 claims description 61
108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 59
102100035290 Fibroblast growth factor 13 Human genes 0.000 claims description 58
101100310657 Mus musculus Sox1 gene Proteins 0.000 claims description 58
210000002242 embryoid body Anatomy 0.000 claims description 31
238000011161 development Methods 0.000 claims description 30
230000018109 developmental process Effects 0.000 claims description 30
210000004129 prosencephalon Anatomy 0.000 claims description 27
101000576323 Homo sapiens Motor neuron and pancreas homeobox protein 1 Proteins 0.000 claims description 21
108010058699 Choline O-acetyltransferase Proteins 0.000 claims description 17
101150092239 OTX2 gene Proteins 0.000 claims description 13
101150004541 HOXC8 gene Proteins 0.000 claims description 12
238000012360 testing method Methods 0.000 claims description 12
150000001875 compounds Chemical class 0.000 claims description 11
238000012258 culturing Methods 0.000 claims description 9
239000003102 growth factor Substances 0.000 claims description 9
210000003061 neural cell Anatomy 0.000 claims description 9
230000001360 synchronised effect Effects 0.000 claims description 9
102100028072 Fibroblast growth factor 4 Human genes 0.000 claims description 7
101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 claims description 7
108091006774 SLC18A3 Proteins 0.000 claims description 6
102100039452 Vesicular acetylcholine transporter Human genes 0.000 claims description 6
102100037665 Fibroblast growth factor 9 Human genes 0.000 claims description 5
101001027380 Homo sapiens Fibroblast growth factor 9 Proteins 0.000 claims description 5
101100451924 Mus musculus Hoxb6 gene Proteins 0.000 claims description 5
101100232284 Mus musculus Hoxc5 gene Proteins 0.000 claims description 5
102000007354 PAX6 Transcription Factor Human genes 0.000 claims description 5
-1 Bfl Proteins 0.000 claims description 4
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims description 4
229960004373 acetylcholine Drugs 0.000 claims description 4
230000001902 propagating effect Effects 0.000 claims description 4
101100071843 Mus musculus Hoxb1 gene Proteins 0.000 claims description 3
102100037680 Fibroblast growth factor 8 Human genes 0.000 claims 5
101001027382 Homo sapiens Fibroblast growth factor 8 Proteins 0.000 claims 5
101150081664 PAX6 gene Proteins 0.000 claims 4
230000011712 cell development Effects 0.000 claims 3
102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 claims 2
101710151768 Aromatic-L-amino-acid decarboxylase Proteins 0.000 claims 2
101001123678 Homo sapiens Phenylethanolamine N-methyltransferase Proteins 0.000 claims 2
102100024611 Phosphatidylethanolamine N-methyltransferase Human genes 0.000 claims 2
102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 1
230000003291 dopaminomimetic effect Effects 0.000 description 72
239000002243 precursor Substances 0.000 description 56
102000003693 Hedgehog Proteins Human genes 0.000 description 45
108090000031 Hedgehog Proteins Proteins 0.000 description 45
108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 45
102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 45
239000002609 medium Substances 0.000 description 42
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 41
229930002330 retinoic acid Natural products 0.000 description 41
229960001727 tretinoin Drugs 0.000 description 41
102000003956 Fibroblast growth factor 8 Human genes 0.000 description 34
108090000368 Fibroblast growth factor 8 Proteins 0.000 description 34
241000699666 Mus <mouse, genus> Species 0.000 description 33
238000011282 treatment Methods 0.000 description 33
230000015572 biosynthetic process Effects 0.000 description 32
230000014509 gene expression Effects 0.000 description 26
238000005755 formation reaction Methods 0.000 description 25
210000004556 brain Anatomy 0.000 description 23
230000036982 action potential Effects 0.000 description 19
210000000276 neural tube Anatomy 0.000 description 19
210000002777 columnar cell Anatomy 0.000 description 18
210000000461 neuroepithelial cell Anatomy 0.000 description 18
101100285407 Mus musculus En1 gene Proteins 0.000 description 17
230000008569 process Effects 0.000 description 17
102100023460 Choline O-acetyltransferase Human genes 0.000 description 16
102000008730 Nestin Human genes 0.000 description 16
108010088225 Nestin Proteins 0.000 description 16
210000005055 nestin Anatomy 0.000 description 16
229960003692 gamma aminobutyric acid Drugs 0.000 description 15
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 15
238000012744 immunostaining Methods 0.000 description 15
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 14
108091023040 Transcription factor Proteins 0.000 description 14
102000040945 Transcription factor Human genes 0.000 description 14
238000004458 analytical method Methods 0.000 description 14
108010007093 dispase Proteins 0.000 description 14
230000002269 spontaneous effect Effects 0.000 description 14
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 13
239000000243 solution Substances 0.000 description 13
230000006698 induction Effects 0.000 description 12
239000003550 marker Substances 0.000 description 12
210000000278 spinal cord Anatomy 0.000 description 12
238000002474 experimental method Methods 0.000 description 11
238000001727 in vivo Methods 0.000 description 10
239000010410 layer Substances 0.000 description 10
210000004940 nucleus Anatomy 0.000 description 10
QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 10
230000000946 synaptic effect Effects 0.000 description 10
238000002054 transplantation Methods 0.000 description 10
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 9
102100039289 Glial fibrillary acidic protein Human genes 0.000 description 9
101710193519 Glial fibrillary acidic protein Proteins 0.000 description 9
210000003050 axon Anatomy 0.000 description 9
210000005046 glial fibrillary acidic protein Anatomy 0.000 description 9
210000001176 projection neuron Anatomy 0.000 description 9
239000000758 substrate Substances 0.000 description 9
210000001519 tissue Anatomy 0.000 description 9
IYGYMKDQCDOMRE-QRWMCTBCSA-N Bicculine Chemical compound O([C@H]1C2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-QRWMCTBCSA-N 0.000 description 8
BAQMYDQNMFBZNA-UHFFFAOYSA-N N-biotinyl-L-lysine Natural products N1C(=O)NC2C(CCCCC(=O)NCCCCC(N)C(O)=O)SCC21 BAQMYDQNMFBZNA-UHFFFAOYSA-N 0.000 description 8
241000283973 Oryctolagus cuniculus Species 0.000 description 8
BAQMYDQNMFBZNA-MNXVOIDGSA-N biocytin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCC[C@H](N)C(O)=O)SC[C@@H]21 BAQMYDQNMFBZNA-MNXVOIDGSA-N 0.000 description 8
238000010348 incorporation Methods 0.000 description 8
239000012981 Hank's balanced salt solution Substances 0.000 description 7
102000008763 Neurofilament Proteins Human genes 0.000 description 7
108010088373 Neurofilament Proteins Proteins 0.000 description 7
230000001464 adherent effect Effects 0.000 description 7
229960005070 ascorbic acid Drugs 0.000 description 7
235000010323 ascorbic acid Nutrition 0.000 description 7
239000011668 ascorbic acid Substances 0.000 description 7
102000014823 calbindin Human genes 0.000 description 7
108060001061 calbindin Proteins 0.000 description 7
210000003169 central nervous system Anatomy 0.000 description 7
230000000694 effects Effects 0.000 description 7
238000002955 isolation Methods 0.000 description 7
230000003988 neural development Effects 0.000 description 7
210000005044 neurofilament Anatomy 0.000 description 7
230000004031 neuronal differentiation Effects 0.000 description 7
210000004248 oligodendroglia Anatomy 0.000 description 7
238000007747 plating Methods 0.000 description 7
238000003757 reverse transcription PCR Methods 0.000 description 7
102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 6
108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 6
101001053263 Homo sapiens Insulin gene enhancer protein ISL-1 Proteins 0.000 description 6
102100024392 Insulin gene enhancer protein ISL-1 Human genes 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
210000005056 cell body Anatomy 0.000 description 6
230000008859 change Effects 0.000 description 6
239000000306 component Substances 0.000 description 6
230000002999 depolarising effect Effects 0.000 description 6
230000002255 enzymatic effect Effects 0.000 description 6
230000002964 excitative effect Effects 0.000 description 6
229940050410 gluconate Drugs 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
210000001161 mammalian embryo Anatomy 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 5
102000004058 Leukemia inhibitory factor Human genes 0.000 description 5
108090000581 Leukemia inhibitory factor Proteins 0.000 description 5
108010002822 Phenylethanolamine N-Methyltransferase Proteins 0.000 description 5
102100028917 Phenylethanolamine N-methyltransferase Human genes 0.000 description 5
102100034026 RNA-binding protein Musashi homolog 1 Human genes 0.000 description 5
101710129077 RNA-binding protein Musashi homolog 1 Proteins 0.000 description 5
210000001130 astrocyte Anatomy 0.000 description 5
238000004113 cell culture Methods 0.000 description 5
210000004748 cultured cell Anatomy 0.000 description 5
239000003814 drug Substances 0.000 description 5
210000002950 fibroblast Anatomy 0.000 description 5
229960002897 heparin Drugs 0.000 description 5
229920000669 heparin Polymers 0.000 description 5
210000001020 neural plate Anatomy 0.000 description 5
230000000644 propagated effect Effects 0.000 description 5
230000004044 response Effects 0.000 description 5
239000000523 sample Substances 0.000 description 5
210000000130 stem cell Anatomy 0.000 description 5
239000000725 suspension Substances 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 5
IAWXTSMHXFRLQR-UHFFFAOYSA-N 2,3-bis($l^{1}-oxidanyl)-7-nitroquinoxaline-6-carbonitrile Chemical compound O=C1C(=O)N=C2C=C(C#N)C([N+](=O)[O-])=CC2=N1 IAWXTSMHXFRLQR-UHFFFAOYSA-N 0.000 description 4
WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
102000009024 Epidermal Growth Factor Human genes 0.000 description 4
101800003838 Epidermal growth factor Proteins 0.000 description 4
108700005087 Homeobox Genes Proteins 0.000 description 4
108010048671 Homeodomain Proteins Proteins 0.000 description 4
102000009331 Homeodomain Proteins Human genes 0.000 description 4
101100074807 Mus musculus Lhx3 gene Proteins 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 4
229930040373 Paraformaldehyde Natural products 0.000 description 4
208000018737 Parkinson disease Diseases 0.000 description 4
241000700159 Rattus Species 0.000 description 4
241000283984 Rodentia Species 0.000 description 4
108010087230 Sincalide Proteins 0.000 description 4
241001279009 Strychnos toxifera Species 0.000 description 4
102000001435 Synapsin Human genes 0.000 description 4
108050009621 Synapsin Proteins 0.000 description 4
238000004115 adherent culture Methods 0.000 description 4
239000000427 antigen Substances 0.000 description 4
AACMFFIUYXGCOC-UHFFFAOYSA-N bicuculline Natural products CN1CCc2cc3OCOc3cc2C1C4OCc5c6OCOc6ccc45 AACMFFIUYXGCOC-UHFFFAOYSA-N 0.000 description 4
210000003855 cell nucleus Anatomy 0.000 description 4
238000012512 characterization method Methods 0.000 description 4
IYGYMKDQCDOMRE-UHFFFAOYSA-N d-Bicucullin Natural products CN1CCC2=CC=3OCOC=3C=C2C1C1OC(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-UHFFFAOYSA-N 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
229940116977 epidermal growth factor Drugs 0.000 description 4
239000000835 fiber Substances 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
210000005260 human cell Anatomy 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
238000002372 labelling Methods 0.000 description 4
239000013642 negative control Substances 0.000 description 4
210000002241 neurite Anatomy 0.000 description 4
210000004498 neuroglial cell Anatomy 0.000 description 4
210000000956 olfactory bulb Anatomy 0.000 description 4
229920002866 paraformaldehyde Polymers 0.000 description 4
108010057417 polysialyl neural cell adhesion molecule Proteins 0.000 description 4
230000035755 proliferation Effects 0.000 description 4
238000012216 screening Methods 0.000 description 4
IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 4
229960005453 strychnine Drugs 0.000 description 4
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 3
102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 3
108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 3
108010078791 Carrier Proteins Proteins 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
108700014808 Homeobox Protein Nkx-2.2 Proteins 0.000 description 3
101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 3
101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 3
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 3
102000019040 Nuclear Antigens Human genes 0.000 description 3
108010051791 Nuclear Antigens Proteins 0.000 description 3
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 3
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 3
102000000813 Proto-Oncogene Proteins c-ret Human genes 0.000 description 3
108010001648 Proto-Oncogene Proteins c-ret Proteins 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
102000004874 Synaptophysin Human genes 0.000 description 3
108090001076 Synaptophysin Proteins 0.000 description 3
102000004142 Trypsin Human genes 0.000 description 3
108090000631 Trypsin Proteins 0.000 description 3
230000009471 action Effects 0.000 description 3
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
210000002459 blastocyst Anatomy 0.000 description 3
210000005013 brain tissue Anatomy 0.000 description 3
229950004398 broxuridine Drugs 0.000 description 3
201000010099 disease Diseases 0.000 description 3
210000005064 dopaminergic neuron Anatomy 0.000 description 3
239000003797 essential amino acid Substances 0.000 description 3
235000020776 essential amino acid Nutrition 0.000 description 3
230000000763 evoking effect Effects 0.000 description 3
230000001747 exhibiting effect Effects 0.000 description 3
230000001605 fetal effect Effects 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
210000001320 hippocampus Anatomy 0.000 description 3
210000004408 hybridoma Anatomy 0.000 description 3
210000003016 hypothalamus Anatomy 0.000 description 3
238000007901 in situ hybridization Methods 0.000 description 3
210000003078 multipolar neuron Anatomy 0.000 description 3
239000002858 neurotransmitter agent Substances 0.000 description 3
230000002474 noradrenergic effect Effects 0.000 description 3
229960002748 norepinephrine Drugs 0.000 description 3
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
229960003104 ornithine Drugs 0.000 description 3
108010017843 platelet-derived growth factor A Proteins 0.000 description 3
239000000047 product Substances 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
230000008439 repair process Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
230000036390 resting membrane potential Effects 0.000 description 3
239000011734 sodium Substances 0.000 description 3
238000003860 storage Methods 0.000 description 3
210000003523 substantia nigra Anatomy 0.000 description 3
210000000225 synapse Anatomy 0.000 description 3
CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 3
229950010357 tetrodotoxin Drugs 0.000 description 3
CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 3
229950003937 tolonium Drugs 0.000 description 3
HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 3
230000002110 toxicologic effect Effects 0.000 description 3
231100000027 toxicology Toxicity 0.000 description 3
239000012588 trypsin Substances 0.000 description 3
210000004515 ventral tegmental area Anatomy 0.000 description 3
VOROEQBFPPIACJ-SCSAIBSYSA-N (2r)-2-amino-5-phosphonopentanoic acid Chemical compound OC(=O)[C@H](N)CCCP(O)(O)=O VOROEQBFPPIACJ-SCSAIBSYSA-N 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
241001076388 Fimbria Species 0.000 description 2
102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
102100037852 Insulin-like growth factor I Human genes 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
238000012897 Levenberg–Marquardt algorithm Methods 0.000 description 2
239000012580 N-2 Supplement Substances 0.000 description 2
102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 2
101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
238000000692 Student's t-test Methods 0.000 description 2
206010043276 Teratoma Diseases 0.000 description 2
102000000307 Transcription factor SOX-1 Human genes 0.000 description 2
108050008750 Transcription factor SOX-1 Proteins 0.000 description 2
102000004243 Tubulin Human genes 0.000 description 2
108090000704 Tubulin Proteins 0.000 description 2
241000251539 Vertebrata <Metazoa> Species 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
239000000853 adhesive Substances 0.000 description 2
230000001070 adhesive effect Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
210000000133 brain stem Anatomy 0.000 description 2
235000010633 broth Nutrition 0.000 description 2
238000004422 calculation algorithm Methods 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000004186 co-expression Effects 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
210000000877 corpus callosum Anatomy 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000007850 degeneration Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
210000001654 germ layer Anatomy 0.000 description 2
229930195712 glutamate Natural products 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
210000004884 grey matter Anatomy 0.000 description 2
230000000971 hippocampal effect Effects 0.000 description 2
238000003365 immunocytochemistry Methods 0.000 description 2
238000010166 immunofluorescence Methods 0.000 description 2
238000002991 immunohistochemical analysis Methods 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
210000001153 interneuron Anatomy 0.000 description 2
238000007914 intraventricular administration Methods 0.000 description 2
210000003140 lateral ventricle Anatomy 0.000 description 2
230000007774 longterm Effects 0.000 description 2
230000035800 maturation Effects 0.000 description 2
238000005259 measurement Methods 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000028161 membrane depolarization Effects 0.000 description 2
239000003068 molecular probe Substances 0.000 description 2
208000005264 motor neuron disease Diseases 0.000 description 2
210000001577 neostriatum Anatomy 0.000 description 2
210000000653 nervous system Anatomy 0.000 description 2
230000004766 neurogenesis Effects 0.000 description 2
230000014511 neuron projection development Effects 0.000 description 2
229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 2
230000001242 postsynaptic effect Effects 0.000 description 2
230000035935 pregnancy Effects 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
238000011002 quantification Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000007261 regionalization Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
210000001082 somatic cell Anatomy 0.000 description 2
208000020431 spinal cord injury Diseases 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
238000004114 suspension culture Methods 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
230000005062 synaptic transmission Effects 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
210000004885 white matter Anatomy 0.000 description 2
239000002023 wood Substances 0.000 description 2
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
229930182837 (R)-adrenaline Natural products 0.000 description 1
PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
RPXVIAFEQBNEAX-UHFFFAOYSA-N 6-Cyano-7-nitroquinoxaline-2,3-dione Chemical compound N1C(=O)C(=O)NC2=C1C=C([N+](=O)[O-])C(C#N)=C2 RPXVIAFEQBNEAX-UHFFFAOYSA-N 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
108091023043 Alu Element Proteins 0.000 description 1
241000269350 Anura Species 0.000 description 1
FTEDXVNDVHYDQW-UHFFFAOYSA-N BAPTA Chemical compound OC(=O)CN(CC(O)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(O)=O)CC(O)=O FTEDXVNDVHYDQW-UHFFFAOYSA-N 0.000 description 1
102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
241000284156 Clerodendrum quadriloculare Species 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
241000252212 Danio rerio Species 0.000 description 1
102000007260 Deoxyribonuclease I Human genes 0.000 description 1
108010008532 Deoxyribonuclease I Proteins 0.000 description 1
SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000900767 Homo sapiens Protein cornichon homolog 1 Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
102000012750 Membrane Glycoproteins Human genes 0.000 description 1
108010090054 Membrane Glycoproteins Proteins 0.000 description 1
102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
101100518992 Mus musculus Pax2 gene Proteins 0.000 description 1
108010083674 Myelin Proteins Proteins 0.000 description 1
102000006386 Myelin Proteins Human genes 0.000 description 1
101150026563 NR4A2 gene Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
102100021852 Neuronal cell adhesion molecule Human genes 0.000 description 1
101710130688 Neuronal cell adhesion molecule Proteins 0.000 description 1
108010032788 PAX6 Transcription Factor Proteins 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
208000037273 Pathologic Processes Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
102100022049 Protein cornichon homolog 1 Human genes 0.000 description 1
239000005700 Putrescine Substances 0.000 description 1
101100184491 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MNR2 gene Proteins 0.000 description 1
108010052164 Sodium Channels Proteins 0.000 description 1
102000018674 Sodium Channels Human genes 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
108090000901 Transferrin Proteins 0.000 description 1
108010020033 Vesicular Monoamine Transport Proteins Proteins 0.000 description 1
102000009659 Vesicular Monoamine Transport Proteins Human genes 0.000 description 1
102000016913 Voltage-Gated Sodium Channels Human genes 0.000 description 1
108010053752 Voltage-Gated Sodium Channels Proteins 0.000 description 1
230000004913 activation Effects 0.000 description 1
210000002934 adrenergic neuron Anatomy 0.000 description 1
230000003321 amplification Effects 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000010171 animal model Methods 0.000 description 1
238000000137 annealing Methods 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
229940112869 bone morphogenetic protein Drugs 0.000 description 1
230000004641 brain development Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
210000004413 cardiac myocyte Anatomy 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
238000002659 cell therapy Methods 0.000 description 1
230000007248 cellular mechanism Effects 0.000 description 1
210000004289 cerebral ventricle Anatomy 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
230000008045 co-localization Effects 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
230000003750 conditioning effect Effects 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000011461 current therapy Methods 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000009849 deactivation Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
210000001787 dendrite Anatomy 0.000 description 1
230000002074 deregulated effect Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
230000028436 dopamine uptake Effects 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000007877 drug screening Methods 0.000 description 1
210000003981 ectoderm Anatomy 0.000 description 1
230000007831 electrophysiology Effects 0.000 description 1
238000002001 electrophysiology Methods 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
210000001900 endoderm Anatomy 0.000 description 1
229960005139 epinephrine Drugs 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
238000010304 firing Methods 0.000 description 1
239000000834 fixative Substances 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
230000002518 glial effect Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000000848 glutamatergic effect Effects 0.000 description 1
210000000020 growth cone Anatomy 0.000 description 1
210000003128 head Anatomy 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
230000001744 histochemical effect Effects 0.000 description 1
238000005286 illumination Methods 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
238000010185 immunofluorescence analysis Methods 0.000 description 1
238000013115 immunohistochemical detection Methods 0.000 description 1
238000011532 immunohistochemical staining Methods 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
210000002660 insulin-secreting cell Anatomy 0.000 description 1
230000010354 integration Effects 0.000 description 1
239000013067 intermediate product Substances 0.000 description 1
210000002425 internal capsule Anatomy 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000000185 intracerebroventricular administration Methods 0.000 description 1
230000003902 lesion Effects 0.000 description 1
229960004502 levodopa Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
210000005171 mammalian brain Anatomy 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000012533 medium component Substances 0.000 description 1
210000003716 mesoderm Anatomy 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
238000012895 mono-exponential function Methods 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
230000006740 morphological transformation Effects 0.000 description 1
230000008271 nervous system development Effects 0.000 description 1
210000005155 neural progenitor cell Anatomy 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
101710135378 pH 6 antigen Proteins 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000009054 pathological process Effects 0.000 description 1
238000000059 patterning Methods 0.000 description 1
239000004033 plastic Substances 0.000 description 1
239000000088 plastic resin Substances 0.000 description 1
108010055896 polyornithine Proteins 0.000 description 1
229920002714 polyornithine Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000009696 proliferative response Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
239000000700 radioactive tracer Substances 0.000 description 1
238000007670 refining Methods 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000002356 single layer Substances 0.000 description 1
150000003385 sodium Chemical class 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229960001471 sodium selenite Drugs 0.000 description 1
239000011781 sodium selenite Substances 0.000 description 1
235000015921 sodium selenite Nutrition 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000009168 stem cell therapy Methods 0.000 description 1
238000009580 stem-cell therapy Methods 0.000 description 1
210000002536 stromal cell Anatomy 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
238000010998 test method Methods 0.000 description 1
210000001103 thalamus Anatomy 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
239000012581 transferrin Substances 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
210000002993 trophoblast Anatomy 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
230000000007 visual effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/44—Thiols, e.g. mercaptoethanol
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/46—Amines, e.g. putrescine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/90—Polysaccharides
- C12N2501/91—Heparin
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Zoology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Neurology (AREA)
Neurosurgery (AREA)
General Health & Medical Sciences (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Developmental Biology & Embryology (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Reproductive Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Gynecology & Obstetrics (AREA)
Psychology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AU2004269361A 2003-08-29 2004-08-27 Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells Expired AU2004269361B2 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US49883103P	2003-08-29	2003-08-29
US60/498,831		2003-08-29
US49957003P	2003-09-02	2003-09-02
US60/499,570		2003-09-02
PCT/US2004/027841 WO2005021720A2 (fr)	2003-08-29	2004-08-27	Procede de differentiation in vitro de cellules souches neuronales, de neurones moteurs et de neurones de dopamine provenant de cellules souches embryonnaires de primates

Publications (2)

Publication Number	Publication Date
AU2004269361A1 AU2004269361A1 (en)	2005-03-10
AU2004269361B2 true AU2004269361B2 (en)	2010-05-20

Family

ID=34278616

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2004269361A Expired AU2004269361B2 (en)	2003-08-29	2004-08-27	Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells

Country Status (8)

Country	Link
EP (1)	EP1670901A4 (fr)
JP (2)	JP2007503811A (fr)
KR (2)	KR20080109943A (fr)
AU (1)	AU2004269361B2 (fr)
CA (1)	CA2536588C (fr)
GB (1)	GB2421029B (fr)
IL (2)	IL173832A (fr)
WO (1)	WO2005021720A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8153424B2 (en)	2001-10-03	2012-04-10	Wisconsin Alumni Research Foundation	Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells
US7588937B2 (en)	2001-10-03	2009-09-15	Wisconsin Alumni Research Foundation	Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells
US7632679B2 (en) *	2002-07-16	2009-12-15	The Trustees Of Columbia University In The City Of New York	Systems and methods for screening for modulators of neural differentiation
JP4792290B2 (ja) *	2005-12-27	2011-10-12	財団法人東京都医学総合研究所	神経幹細胞の製造方法
EA027648B9 (ru)	2006-03-07	2018-01-31	Гита Шроф	КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ЭМБРИОНАЛЬНЫЕ СТВОЛОВЫЕ КЛЕТКИ ЧЕЛОВЕКА (ЭСКч) ИЛИ КЛЕТКИ-ПРОИЗВОДНЫЕ ЭСКч, И ИХ ПРИМЕНЕНИЕ
KR100838013B1 (ko) *	2006-06-07	2008-06-12	제일약품주식회사	인간배아줄기세포로부터 단계적 선별법을 통해 고수율로신경전구세포, 신경세포 및 기능성 도파민신경세포를생성하는 방법
CA2721952C (fr)	2008-04-22	2019-11-12	Regenerative Research Foundation	Cellules souches de l'epithelium pigmentaire retinien
KR101168053B1 (ko) *	2009-11-06	2012-07-24	연세대학교 산학협력단	효율적이고 보편적인 전분화능 줄기세포의 신경세포 분화 유도방법
CN103052707A (zh)	2010-07-30	2013-04-17	剑桥实业有限公司	人类多能细胞的皮层生成
US9487752B2 (en)	2011-03-30	2016-11-08	Cellular Dynamics International, Inc.	Priming of pluripotent stem cells for neural differentiation
JP6015112B2 (ja) *	2012-05-11	2016-10-26	株式会社ニコン	細胞評価装置、細胞評価方法およびプログラム
MA67580B1 (fr) *	2015-11-12	2024-09-30	F. Hoffmann-La Roche Ag	Oligonucléotides pour induire l'expression de paternal ube3a
WO2017123806A1 (fr)	2016-01-12	2017-07-20	Cedars-Sinai Medical Center	Procédé de suivi non destructeur de processus biologiques dans des systèmes de culture de tissu microfluidiques
WO2017136479A1 (fr)	2016-02-01	2017-08-10	Cedars-Sinai Medical Center	Systèmes et procédés de mise en croissance de cellules intestinales dans des dispositifs microfluidiques
JPWO2017209290A1 (ja) *	2016-06-03	2019-04-11	国立大学法人京都大学	多能性幹細胞由来運動ニューロンの製造及びその用途
JP6376196B2 (ja) *	2016-09-29	2018-08-22	株式会社ニコン	細胞評価装置、細胞評価方法およびプログラム
WO2018140647A1 (fr)	2017-01-25	2018-08-02	Cedars-Sinai Medical Center	Induction in vitro de différenciation de type mammaire à partir de cellules souches pluripotentes humaines
US11767513B2 (en)	2017-03-14	2023-09-26	Cedars-Sinai Medical Center	Neuromuscular junction
WO2018176001A2 (fr)	2017-03-24	2018-09-27	Cedars-Sinai Medical Center	Procédés et compositions pour la production d'épithélium de trompes de fallope
CN108048399B (zh) *	2017-11-13	2021-03-23	昆明医科大学	一种meth诱导树鼩多巴胺神经元原代细胞自噬的方法
JP2019106895A (ja) *	2017-12-15	2019-07-04	インダストリー‐ユニバーシティーコーぺレーションファンデーションハンヤンユニバーシティ	神経幹細胞または神経前駆細胞からドーパミン神経細胞への分化方法
EP3768823A4 (fr)	2018-03-23	2022-03-09	Cedars-Sinai Medical Center	Procédés d'utilisation de cellules des îlots pancréatiques
US11981918B2 (en)	2018-04-06	2024-05-14	Cedars-Sinai Medical Center	Differentiation technique to generate dopaminergic neurons from induced pluripotent stem cells
US12241085B2 (en)	2018-04-06	2025-03-04	Cedars-Sinai Medical Center	Human pluripotent stem cell derived neurodegenerative disease models on a microfluidic chip
JP2021532736A (ja) *	2018-06-06	2021-12-02	ザリージェンツオブザユニバーシティオブカリフォルニアThe Regents Of The University Of California	神経幹細胞組成物および神経変性障害を処置するための方法
JP6798533B2 (ja) *	2018-07-26	2020-12-09	株式会社ニコン	細胞評価装置、インキュベータおよびプログラム
CN114375328B (zh) *	2019-09-06	2024-12-27	学校法人庆应义塾	包含胶质前体细胞的细胞聚集体的制备方法
WO2022098895A1 (fr) *	2020-11-04	2022-05-12	The Regents Of The University Of Michigan	Dispositifs microfluidiques et procédés de développement de tissus du type tube neural ou sphéroïdes neuraux
JP7235027B2 (ja) *	2020-11-16	2023-03-08	株式会社ニコン	細胞評価装置、インキュベータおよびプログラム

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020009743A1 (en) *	2000-05-17	2002-01-24	Carpenter Melissa K.	Neural progenitor cell populations
US20020168763A1 (en) *	2000-11-30	2002-11-14	Yan Wen Liang	Isolated homozygous stem cells, differentiated cells derived therefrom, and materials and methods for making and using same
US20030068819A1 (en) *	2001-10-03	2003-04-10	Su-Chun Zhang	Method of in vitro differentiation of transplantatable neural precursor cells from primate embryonic stem cells
US20030211605A1 (en) *	2001-05-01	2003-11-13	Lee Sang-Hun	Derivation of midbrain dopaminergic neurons from embryonic stem cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7144997B2 (en) *	1997-07-24	2006-12-05	Curis, Inc.	Vertebrate embryonic patterning-inducing proteins, compositions and uses related therto
CA2298506A1 (fr) *	1997-08-04	1999-02-11	The Regents Of The University Of California	Procede de traitement des deficits neurologiques
AU2001259323A1 (en) *	2000-05-01	2001-11-12	Sang-Hun Lee	Derivation of midbrain dopaminergic neurons from embryonic stem cells

2004
- 2004-08-27 GB GB0605851A patent/GB2421029B/en not_active Expired - Lifetime
- 2004-08-27 WO PCT/US2004/027841 patent/WO2005021720A2/fr not_active Ceased
- 2004-08-27 KR KR1020087028900A patent/KR20080109943A/ko not_active Ceased
- 2004-08-27 AU AU2004269361A patent/AU2004269361B2/en not_active Expired
- 2004-08-27 JP JP2006524872A patent/JP2007503811A/ja not_active Withdrawn
- 2004-08-27 CA CA2536588A patent/CA2536588C/fr not_active Expired - Lifetime
- 2004-08-27 KR KR1020067004226A patent/KR20060115351A/ko not_active Ceased
- 2004-08-27 EP EP04782339A patent/EP1670901A4/fr not_active Withdrawn
2006
- 2006-02-20 IL IL173832A patent/IL173832A/en active IP Right Grant
2009
- 2009-04-28 IL IL198450A patent/IL198450A/en active IP Right Grant
2010
- 2010-01-28 JP JP2010017013A patent/JP5529561B2/ja not_active Expired - Lifetime

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020009743A1 (en) *	2000-05-17	2002-01-24	Carpenter Melissa K.	Neural progenitor cell populations
US20020168763A1 (en) *	2000-11-30	2002-11-14	Yan Wen Liang	Isolated homozygous stem cells, differentiated cells derived therefrom, and materials and methods for making and using same
US20030211605A1 (en) *	2001-05-01	2003-11-13	Lee Sang-Hun	Derivation of midbrain dopaminergic neurons from embryonic stem cells
US20030068819A1 (en) *	2001-10-03	2003-04-10	Su-Chun Zhang	Method of in vitro differentiation of transplantatable neural precursor cells from primate embryonic stem cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MUJTABA et al. Developmental Biology, 1999, vol. 214, no. 1, pages 113-127 *
ZHANG et al. Nature Biotechnology, 2001, vol. 19, no.12, pages 1129-1133 *

Also Published As

Publication number	Publication date
IL173832A (en)	2011-02-28
CA2536588A1 (fr)	2005-03-10
GB2421029B (en)	2008-04-09
KR20080109943A (ko)	2008-12-17
AU2004269361A1 (en)	2005-03-10
CA2536588C (fr)	2018-04-24
EP1670901A2 (fr)	2006-06-21
IL198450A (en)	2011-01-31
GB0605851D0 (en)	2006-05-03
GB2421029A (en)	2006-06-14
WO2005021720A2 (fr)	2005-03-10
WO2005021720A3 (fr)	2005-05-19
JP2007503811A (ja)	2007-03-01
EP1670901A4 (fr)	2007-09-05
KR20060115351A (ko)	2006-11-08
IL173832A0 (en)	2006-07-05
JP5529561B2 (ja)	2014-06-25
JP2010162024A (ja)	2010-07-29

Publication	Publication Date	Title
AU2004269361B2 (en)	2010-05-20	Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells
Li	2014	Zhang, l
US8153424B2 (en)	2012-04-10	Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells
US9080151B2 (en)	2015-07-14	Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells
US6887706B2 (en)	2005-05-03	Method of in vitro differentiation of transplantable neural precursor cells from primate embryonic stem cells
US8133730B2 (en)	2012-03-13	Generation of neural stem cells from undifferentiated human embryonic stem cells
WO2009024448A1 (fr)	2009-02-26	Génération de cellules neuronales à partir de cellules souches pluripotentes
JP2024513912A (ja)	2024-03-27	ドーパミン作動性前駆細胞（ｐｒｅｃｕｒｓｏｒｃｅｌｌ）及び使用方法
EP1179046B1 (fr)	2006-03-08	Cellules precurseurs a restriction de lignage, isolees a partir du tube neural de souris et de cellules souches embryonnaires de souris
US10160951B2 (en)	2018-12-25	Stem cells from the mammalian neural plate
AU2003229132B2 (en)	2009-06-11	Generation of neural stem cells from undifferentiated human embryonic stem cells
HK1161298A (en)	2012-08-24	Stem cells
HK1158679A (en)	2012-07-20	Stem cells
AU4826200A (en)	2000-11-21	Lineage-restricted precursor cells isolated from mouse neural tube and mouse embryonic stem cells

Legal Events

Date	Code	Title	Description
2010-08-26	DA3	Amendments made section 104	Free format text: THE NATURE OF THE AMENDMENT IS: DELETE CO-INVENTORS THOMSON, JAMES A; DUNCAN, IAN DAVID
2010-09-30	FGA	Letters patent sealed or granted (standard patent)
2024-09-19	MK14	Patent ceased section 143(a) (annual fees not paid) or expired